$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Which generation of targeted drugs does Crizotinib (Xalkore) belong to and analysis of its clinical advantages
2026-02-01 22:25:32
Check Details
Instructions on whether aprocitentan is available in domestic pharmacies and hospitals
2026-02-01 22:25:32
Check Details
Analysis of the reasons why some people do not recommend the use of tilpotide/tilsiparatide (Mufengda)
2026-02-01 22:25:32
Check Details
Interpretation of the latest market reference price of pitobrutinib/pirtobrutinib in 2025
2026-02-01 22:25:32
Check Details
The latest news on whether Talazoparib has been included in medical insurance in the country
2026-02-01 22:25:32
Check Details
Crizotinib (Xalkori) capsule dosage form appearance and detailed instructions on how to take it
2026-02-01 22:25:32
Check Details
What kind of drugs does aprocitentan belong to and its main pharmacological effects?
2026-02-01 22:25:32
Check Details
Tirpotide/Tirzepatid (Tirzepatide) formal purchasing channels and pharmacies purchasing precautions
2026-02-01 22:25:32
Check Details
Pitobrutinib/Pitobrutinib (Zepali) indication scope and introduction to the main diseases treated
2026-02-01 22:25:32
Check Details
Detailed description of Talazoparib medical insurance reimbursement policy and operating procedures
2026-02-01 22:25:32
Check Details
The latest market price and purchasing reference of Crizotinib in 2025
2026-02-01 22:25:32
Check Details
Analysis of the efficacy and patient feedback of aprocitentan in the treatment of pulmonary arterial hypertension
2026-02-01 22:25:32
Check Details
1
2
...
2359
2360
2361
2362
2363
2364
2365
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
5
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
6
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
7
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
8
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
9
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
10
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
11
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
12
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy